Corpus ID: 46682224

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.

@article{Amin1997RPR1A,
  title={RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.},
  author={D. Amin and R. Z. Rutledge and S. Needle and H. Galczenski and K. Neuenschwander and A. Scotese and M. P. Maguire and R. C. Bush and D. Hele and G. Bilder and Mark H. Perrone},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1997},
  volume={281 2},
  pages={
          746-52
        }
}
  • D. Amin, R. Z. Rutledge, +8 authors Mark H. Perrone
  • Published 1997
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • Squalene synthase catalyzes the reductive dimerization of two molecules of farnesyl pyrophosphate to form squalene and is the first committed step in sterol synthesis. A specific inhibitor of squalene synthase would inhibit cholesterol biosynthesis but not prevent the formation of other products of the isoprenoid pathway, such as dolichol and ubiquinone. RPR 107393 [3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2-2-2]octane dihydrochloride] and its R and S enantiomers are potent inhibitors… CONTINUE READING
    64 Citations
    Squalene epoxidase as hypocholesterolemic drug target revisited.
    • 85

    References

    SHOWING 1-10 OF 22 REFERENCES
    Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo.
    • 170